Strategic partnerships Leverage Fry Laboratories long-standing collaboration history with Beckman Coulter and BioID Genomics to position joint value propositions in rapid NGS diagnostics, automation integration, and scalable infectious disease testing for potential enterprise clients.

NGS leadership Highlight Fry Laboratories’ experience developing next generation sequencing assays for SARS-CoV-2 and its ongoing emphasis on sequencing-based pathogen identification to attract labs seeking advanced genomic diagnostics capabilities.

Capable scale Although a small team, Fry Laboratories’ participation in CAP and API quality control programs and worldwide testing capabilities can be framed as a flexible, compliant partner for scalable diagnostic services and distributed testing networks.

Targeted niches Focus on chronic inflammatory and vector-borne diseases where Fry has research emphasis, offering specialized diagnostic and biomarker services to clinics and research institutions seeking niche expertise and expanded testing panels.

Digital presence Emphasize their tech-enabled testing workflow and modern data capabilities (NGS, sequencing, immunology, and bioinformatics) to attract enterprise buyers prioritizing integrated lab-as-a-service models and turnkey reporting.